Genetic Testing Insurance Claim Denied? How to Appeal

Insurance denials for genetic testing are widespread despite the growing role these tests play in cancer prevention, rare disease diagnosis, and precision medicine. Whether the denial involves hereditary cancer screening, pharmacogenomic testing, or tumour profiling, understanding the specific basis for denial and the applicable legal and clinical framework is essential for building an effective appeal.

Why Insurers Deny Genetic Testing Claims

Medical necessity not established. The insurer's utilisation reviewer determined that the test does not meet their internal clinical criteria for your personal or family history profile. These internal criteria are often more restrictive than NCCN, USPSTF, or ACMG guidelines.

Prior authorisation not obtained. Genetic testing frequently requires pre-approval. Claims submitted without documented prior authorisation are denied regardless of the clinical appropriateness of the test.

Experimental or investigational designation. Newer multi-gene panels, pharmacogenomic tests, and next-generation sequencing (NGS) panels are sometimes classified as investigational even when they carry CLIA certification, FDA clearance, and endorsement by NCCN, ACMG, or USPSTF.

ACA Section 2713 preventive mandate not applied. For USPSTF-recommended preventive genetic services — particularly BRCA1/2 counselling and testing for qualifying women — ACA Section 2713 (42 U.S.C. § 300gg-13) requires coverage without cost-sharing in non-grandfathered plans. Failure to apply this mandate may constitute a federal law violation.

Documentation insufficient. The clinical records submitted do not adequately document the specific indication — family history details, personal history of cancer, hereditary syndrome criteria — required to establish medical necessity for the test.

How to Appeal a Genetic Testing Denial

Step 1: Identify the Specific Test and the Denial Basis

Determine which test was denied and why. BRCA testing, Lynch syndrome panel, hereditary cancer panel, pharmacogenomic testing, tumour profiling, and whole exome/genome sequencing each invoke different coverage standards and legal frameworks. The denial letter should cite the specific policy provision or clinical criterion used.

Step 2: Gather Medical Necessity Documentation from Your Physician

Your ordering physician must provide a detailed letter documenting: the specific clinical indication, your personal and family history details, the guideline criteria met (NCCN risk category, USPSTF criteria, ACMG indications), and the clinical management implications of the test result. Generic letters stating the test is "needed" are insufficient — the letter must address the specific criteria the insurer cited in the denial.

Step 3: Cite ACA and GINA Protections

For USPSTF Grade B preventive services, cite ACA Section 2713 (42 U.S.C. § 300gg-13): "BRCA genetic counseling and testing is a USPSTF Grade B preventive service for women with qualifying family history. Under ACA Section 2713, this service must be covered without cost-sharing in all non-grandfathered plans. This denial may violate federal law." For GINA protections, cite 42 U.S.C. § 2000ff et seq. — the Genetic Information Nondiscrimination Act prohibits using genetic information in coverage decisions and bars premium increases based on genetic test results.

Step 4: Address the Experimental Designation with Regulatory Evidence

For tests classified as experimental, provide: the laboratory's CLIA certification number, any FDA clearance, approval, or breakthrough device designation for the specific test, the NCCN, ACMG, or USPSTF guideline recommending the test for your clinical indication, and published clinical evidence supporting the test's utility. Insurers cannot sustain an experimental designation for a test with FDA recognition and major society guideline endorsement.

Step 5: Verify CPT Codes and Laboratory Network Status

Confirm correct CPT codes were submitted. Key codes: BRCA1/2 sequencing (CPT 81162–81164); hereditary cancer panel (CPT 81432); tumour profiling (CPT 81445, 81455, 81479); pharmacogenomic testing (varies by gene). If incorrect codes were used, request a corrected resubmission. For out-of-network laboratory denials, request a network adequacy exception if no in-network option provides the specific test.

Step 6: Request External Independent Review: Complete Guide" class="auto-link">External Review if the Internal Appeal Fails

Under 45 CFR § 147.136 and 29 CFR § 2560.503-1, you have the right to an independent external review. Request that the external reviewer be a qualified specialist in genetics or oncology with relevant expertise. External reviewers applying NCCN and ACMG guidelines rather than insurer-specific criteria frequently overturn genetic testing denials.

What to Include in Your Appeal

• Denial letter with the specific coverage criterion or policy provision cited
• Ordering physician's letter documenting the clinical indication and applicable guideline criteria
• ACA Section 2713 citation for USPSTF-indicated preventive testing
• NCCN, ACMG, or USPSTF guideline documentation for the specific test and indication
• Laboratory CLIA certification and any FDA recognition documentation

Fight Back With ClaimBack

Genetic testing denials frequently rest on insurer criteria that are more restrictive than federal law and published clinical guidelines require. A targeted appeal citing ACA Section 2713, GINA, and the specific guideline framework inverted to your case gives you a strong path to reversal. ClaimBack generates a professional appeal letter in 3 minutes.

Start your free claim analysis →

Free analysis · No credit card required · Takes 3 minutes

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Internal vs External Insurance Appeal